Spermosens Past Earnings Performance
Past criteria checks 0/6
Spermosens's earnings have been declining at an average annual rate of -32.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 42.7% per year.
Key information
-32.5%
Earnings growth rate
2.8%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | -42.7% |
| Return on equity | -44.3% |
| Net Margin | n/a |
| Next Earnings Update | 28 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Spermosens makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -10 | 4 | 4 |
| 30 Jun 24 | 0 | -11 | 5 | 4 |
| 31 Mar 24 | 0 | -12 | 5 | 5 |
| 31 Dec 23 | 0 | -12 | 6 | 5 |
| 30 Sep 23 | 0 | -20 | 7 | 12 |
| 30 Jun 23 | 0 | -20 | 7 | 12 |
| 31 Mar 23 | 0 | -20 | 8 | 12 |
| 31 Dec 22 | 0 | -19 | 8 | 12 |
| 30 Sep 22 | 5 | -11 | 9 | 4 |
| 30 Jun 22 | 8 | -10 | 10 | 3 |
| 31 Mar 22 | 11 | -8 | 11 | 1 |
| 31 Dec 21 | 12 | -6 | 10 | 0 |
| 30 Sep 21 | 9 | -7 | 9 | 0 |
| 30 Jun 21 | 7 | -5 | 6 | 0 |
| 31 Mar 21 | 4 | -3 | 4 | 0 |
| 31 Dec 20 | 2 | -2 | 3 | 0 |
| 31 Dec 19 | 0 | 0 | 1 | 0 |
Quality Earnings: SPERM is currently unprofitable.
Growing Profit Margin: SPERM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPERM is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.
Accelerating Growth: Unable to compare SPERM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPERM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: SPERM has a negative Return on Equity (-44.32%), as it is currently unprofitable.